GENELUX CORPORATION Deferred Tax Assets, Operating Loss Carryforwards
GENELUX CORPORATION (GNLX) had Deferred Tax Assets, Operating Loss Carryforwards of $93.70 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $93.70M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $70.00M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $22.33K.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $93.70M 10-K · filed 2026-03-19 |
| 2024-12-31 | $70.00M 10-K · filed 2025-03-28 |
| 2023-12-31 | $22.33K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |